AMRZ has now dropped to CHF 38.26 — down 8.2% on the week and roughly 23% below the prices CEO Jan Jenisch paid when he bought the dip in May, sharpening the question of whether the half-year results that landed August 7 changed the fundamental story or simply accelerated a re-rating already in motion.
The results appear to have done real damage. The stock fell just over 10% on August 7, and a second earnings-related event on August 6 shows the same decline embedded in the data — the two readings effectively capture the same post-results repricing. That one-day drop is the largest in the recent history available here, and it dwarfs the near-flat reaction (+0.3%) recorded at the August 10 event. The shares recouped 1.4% on Tuesday but remain bruised, and the monthly loss has now deepened to around 7%.
The lending market is not where the pressure is coming from. Borrow availability is extraordinarily loose — roughly 2,024% as of Tuesday, meaning there are more than 20 shares available to lend for every one already borrowed. That is down sharply from above 3,000% at the start of the week, a move worth watching, but still firmly in territory that signals no meaningful short-side conviction. Cost to borrow has barely moved — running near 0.63%, within the tight band it has occupied all summer. The ORTEX short score ticked up to 30.2, its highest reading of the past two weeks, but the absolute level remains low. This is a stock that the market is selling, not one that short sellers are structurally attacking.
The institutional picture adds nuance. Vanguard filed a new position of 27.7 million shares as of June 30 — a meaningful first entry from a major passive manager. BlackRock added modestly in July. Those flows suggest the broader ownership base was still building into the weakness, even as the stock continued to slide. Against that, the valuation multiples have compressed meaningfully: the price-to-book has fallen around 0.2x in seven days to 1.76x, and the trailing P/E has dropped 1.5 turns to 16.3x over the same period. EV/EBITDA at 9.1x is up slightly on the week, reflecting the debt load rather than equity enthusiasm. The dividend score ranks in the 89th percentile — supported by the special dividend approved in April — and EPS surprise history ranks in the 77th percentile, which sits awkwardly against a post-results selloff of this magnitude.
The peer divergence is notable. HOLN fell only 2.2% on the week while CRH actually gained 2.5% and MLM was nearly flat. VCT and WIE both fell harder — 5.1% and 4.7% respectively — suggesting some sector-wide pressure, but AMRZ's decline is well beyond the peer median. That gap implies the results themselves, not simply the macro backdrop, drove the underperformance.
The insider buying cluster from May — CEO Jenisch's roughly CHF 610,000 in purchases between CHF 48.50 and CHF 49.96, alongside smaller buys from the CMO and CTO — now sits approximately 24% out of the money. The next scheduled earnings event is October 26. Whether the half-year print resolves into a reset or a more sustained re-rating is what the next few weeks of trading will answer.
See the live data behind this article on ORTEX.
Open AMRZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
